|
Post by iamaverb on Feb 12, 2020 19:12:07 GMT
ADVM is gaining traction with their AMD gene editing trials. This is a company founded by Steven Schwartz of ACTC linkage when it was Avalanche, but they finally began the Macular Degeneration trials. Last night they announced a 11 million share dilution at $13.75 and today trades at $15.35. Strength! If only Lanza could have pulled it off.
|
|